Abstract
Cells encounter stress on a daily basis that can damage their DNA and promote malignant transformation, yet the latter rarely occurs. The DNA damage response (DDR) is a highly coordinated signaling pathway that functions to detect and repair DNA damage in cells, inhibiting transformation. However, when DNA damage is so severe that it cannot be repaired, the DDR promotes apoptosis, thus preventing the propagation of abnormal cells. The tumor suppressor protein, p53, is one of the most essential molecules keeping DNA damage in check. Here, we discuss the signaling cascades that activate p53 upon DNA damage and the molecular mechanisms that mediate p53-dependent and -independent apoptosis. Moreover, we discuss the signals that trigger the DDR during malignant propagation and the importance of DNA damage-mediated apoptosis in preventing tumorigenesis.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28:739–45. doi:S1097-2765(07)00783-6 [pii]10.1016/j.molcel.2007.11.015.
Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316–23. doi:nature03097 [pii]10.1038/nature03097.
Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–8. doi:nature08467 [pii]10.1038/nature08467.
Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179–204. doi:S1097-2765(10)00747-1 [pii]10.1016/j.molcel.2010.09.019.
Lindahl T, Barnes DE. Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol. 2000;65:127–33.
Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science. 2010;330:517–21. doi:330/6003/517 [pii]10.1126/science.1192912.
Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191–308.
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–74. doi:10.1038/3507723235077232 [pii].
Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73–112. doi:B978-0-12-380888-2.00003-0 [pii]10.1016/B978-0-12-380888-2.00003-0.
Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle. 2007;6:931–42. doi:4180 [pii].
Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616–27. doi:nrm2450 [pii]10.1038/nrm2450.
Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506. doi:10.1038/nature01368[pii].
Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science. 2005;308:551–4. doi:1108297 [pii]10.1126/science.1108297.
Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 2003;300:1542–8. doi:10.1126/science.1083430300/5625/1542 [pii].
Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science. 2001;294:1713–6. doi:10.1126/science.1065521294/5547/1713 [pii].
Matsuoka S, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6. doi:316/5828/1160 [pii]10.1126/science.1140321.
Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858–68.
Paull TT, et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000;10:886–95. doi:S0960-9822(00)00610-2 [pii].
Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol. 2003;5:255–60. doi:10.1038/ncb945 [pii].
Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421:961–6. doi:10.1038/nature01446 [pii].
Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science. 2002;298:1435–8. doi:10.1126/science.1076182 [pii].
Lou Z, et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell. 2006;21:187–200. doi:S1097-2765(05)01813-7 [pii]10.1016/j.molcel.2005.11.025.
Mochan TA, Venere M, DiTullio Jr RA, Halazonetis TD. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res. 2003;63:8586–91.
Huyen Y, et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature. 2004;432:406–11. doi:nature03114 [pii]10.1038/nature03114.
Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 1999;286:1162–6. doi:7959 [pii].
Zou L, Cortez D, Elledge SJ. Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev. 2002;16:198–208. doi:10.1101/gad.950302.
Wang X, et al. Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. Mol Cell. 2006;23:331–41. doi:S1097-2765(06)00449-7 [pii]10.1016/j.molcel.2006.06.022.
Bao S, et al. ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. Nature. 2001;411:969–74. doi:10.1038/35082110 [pii].
Lee J, Kumagai A, Dunphy WG. Claspin, a Chk1-regulatory protein, monitors DNA replication on chromatin independently of RPA, ATR, and Rad17. Mol Cell. 2003;11:329–40. doi:S1097276503000455 [pii].
Liu Q, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000;14:1448–59.
Sanchez Y, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 1997;277:1497–501.
Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609–22. doi:S0092-8674(09)00511-X [pii]10.1016/j.cell.2009.04.050.
Hirao A, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000;287:1824–7. doi:8333 [pii].
Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ. 2006;13:994–1002. doi:4401908 [pii]10.1038/sj.cdd.4401908.
Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9:402–12. doi:nrm2395 [pii]10.1038/nrm2395.
Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–14. doi:nrc2657 [pii]10.1038/nrc2657.
Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 2003;278:9100–6. doi:10.1074/jbc.M210284200 [pii].
Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13:184–90. doi:ncb0311-184 [pii]10.1038/ncb0311-184.
Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411–24. doi:nrm3376 [pii]10.1038/nrm3376.
Jwa M, Chang P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1alpha-mediated unfolded protein response. Nat Cell Biol. 2012;14:1223–30. doi:ncb2593 [pii]10.1038/ncb2593.
Gorman AM, Healy SJ, Jager R, Samali A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther. 2012;134:306–16. doi:S0163-7258(12)00043-5 [pii]10.1016/j.pharmthera.2012.02.003.
Green DR. Means to an end: apoptosis and other cell death mechanisms. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2011.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231–41. doi:nrm2312 [pii]10.1038/nrm2312.
Dickens LS, Powley IR, Hughes MA, MacFarlane M. The ‘complexities’ of life and death: death receptor signalling platforms. Exp Cell Res. 2012;318:1269–77. doi:S0014-4827(12)00188-7 [pii]10.1016/j.yexcr.2012.04.005.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501. doi:S0092-8674(01)00237-9 [pii].
Scott FL, et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature. 2009;457:1019–22. doi:nature07606 [pii]10.1038/nature07606.
Kischkel FC, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579–88.
Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26–35. doi:10.1038/sj.cdd.4401186 [pii].
Oberst A, et al. Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem. 2010;285:16632–42. doi:M109.095083 [pii]10.1074/jbc.M109.095083.
Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000;2:156–62. doi:10.1038/35004029.
Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621–32. doi:nrm2952 [pii]10.1038/nrm2952.
Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405–13. doi:S0092-8674(00)80501-2 [pii].
Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999;274:11549–56.
Schafer ZT, Kornbluth S. The apoptosome: physiological, developmental, and pathological modes of regulation. Dev Cell. 2006;10:549–61. doi:S1534-5807(06)00169-9 [pii]10.1016/j.devcel.2006.04.008.
Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007;8:405–13. doi:nrm2153 [pii]10.1038/nrm2153.
Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37:299–310. doi:S1097-2765(10)00079-1 [pii]10.1016/j.molcel.2010.01.025.
Llambi F, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44:517–31. doi:S1097-2765(11)00760-X [pii]10.1016/j.molcel.2011.10.001.
Cheng EH, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8:705–11. doi:S1097-2765(01)00320-3 [pii].
Wei MC, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–30. doi:10.1126/science.1059108292/5517/727 [pii].
Willis SN, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:856–9. doi:315/5813/856 [pii]10.1126/science.1133289.
Wei MC, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000;14:2060–71.
Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol. 2000;20:929–35.
Kuwana T, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525–35. doi:S1097276505010774 [pii]10.1016/j.molcel.2005.02.003.
Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15–6. doi:10.1038/358015a0.
Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–31. doi:S0092-8674(00)81871-1 [pii].
Donehower LA, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–21. doi:10.1038/356215a0.
Lang GA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119:861–72. doi:S0092867404010487 [pii]10.1016/j.cell.2004.11.006.
Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303. doi:10.1038/387299a0.
Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A. 2003;100:12009–14. doi:10.1073/pnas.2030930100 [pii].
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–45. doi:0092-8674(92)90644-R [pii].
Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126–32.
Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–31. doi:S0092-8674(09)00459-0 [pii]10.1016/j.cell.2009.04.037.
Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 1995;9:2170–83.
Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol. 2010;20:14–24. doi:S0962-8924(09)00240-2 [pii]10.1016/j.tcb.2009.10.002.
Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 2003;4:371–81. doi:S1535610803002721 [pii].
Chipuk JE, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–4. doi:10.1126/science.1092734303/5660/1010 [pii].
Pietsch EC, et al. The tetramerization domain of p53 is required for efficient BAK oligomerization. Cancer Biol Ther. 2007;6:1576–83. doi:4719 [pii].
Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 2004;6:443–50. doi:10.1038/ncb1123 [pii].
Petros AM, Gunasekera A, Xu N, Olejniczak ET, Fesik SW. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett. 2004;559:171–4. doi:10.1016/S0014-5793(04)00059-6S0014579304000596 [pii].
Mihara M, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11:577–90. doi:S1097276503000509 [pii].
Schuler M, Green DR. Transcription, apoptosis and p53: catch-22. Trends Genet. 2005;21:182–7. doi:S0168-9525(05)00015-6 [pii]10.1016/j.tig.2005.01.001.
Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 2005;309:1732–5. doi:309/5741/1732 [pii]10.1126/science.1114297.
Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008;77:557–82. doi:10.1146/annurev.biochem.77.060806.091238.
Scolnick DM, et al. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 1997;57:3693–6.
Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–9. doi:10.1038/387296a0.
Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A. 1996;93:15335–40.
Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346–55.
Wang Y, et al. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 1993;7:2575–86.
Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90:595–606. doi:S0092-8674(00)80521-8 [pii].
Siliciano JD, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997;11:3471–81.
Shieh SY, Taya Y, Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 1999;18:1815–23. doi:10.1093/emboj/18.7.1815.
Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol. 1999;19:1751–8.
Tibbetts RS, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999;13:152–7.
Unger T, et al. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999;18:1805–14. doi:10.1093/emboj/18.7.1805.
Wu Z, et al. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol. 2002;22:2441–9.
Sluss HK, Armata H, Gallant J, Jones SN. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol. 2004;24:976–84.
Chao C, Herr D, Chun J, Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 2006;25:2615–22. doi:7601167 [pii]10.1038/sj.emboj.7601167.
Maya R, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 2001;15:1067–77. doi:10.1101/gad.886901.
Gannon HS, Woda BA, Jones SN. ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice. Cancer Cell. 2012;21:668–79. doi:S1535-6108(12)00163-8 [pii]10.1016/j.ccr.2012.04.011.
Carter S, Bischof O, Dejean A, Vousden KH. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol. 2007;9:428–35. doi:ncb1562 [pii]10.1038/ncb1562.
Cheng Q, Chen L, Li Z, Lane WS, Chen J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 2009;28:3857–67. doi:emboj2009294 [pii]10.1038/emboj.2009.294.
Gajjar M, et al. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell. 2012;21:25–35. doi:S1535-6108(11)00439-9 [pii]10.1016/j.ccr.2011.11.016.
Khoronenkova SV, et al. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell. 2012;45:801–13. doi:S1097-2765(12)00087-1 [pii]10.1016/j.molcel.2012.01.021.
Cummins JM, et al. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature. 2004;428:1 p following 486. doi:10.1038/nature02501.
Meulmeester E, et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell. 2005;18:565–76. doi:S1097-2765(05)01287-6 [pii]10.1016/j.molcel.2005.04.024.
Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005;24:3411–22. doi:7600812 [pii]10.1038/sj.emboj.7600812.
Okamoto K, et al. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol. 2005;25:9608–20. doi:25/21/9608 [pii]10.1128/MCB.25.21.9608-9620.2005.
Dornan D, et al. ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science. 2006;313:1122–6. doi:313/5790/1122 [pii]10.1126/science.1127335.
Leng RP, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003;112:779–91. doi:S0092867403001934 [pii].
Chen D, et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell. 2005;121:1071–83. doi:S0092-8674(05)00356-9 [pii]10.1016/j.cell.2005.03.037.
Krummel KA, Lee CJ, Toledo F, Wahl GM. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A. 2005;102:10188–93. doi:0503068102 [pii]10.1073/pnas.0503068102.
Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol. 2005;25:5389–95. doi:25/13/5389 [pii]10.1128/MCB.25.13.5389-5395.2005.
Sykes SM, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell. 2006;24:841–51. doi:S1097-2765(06)00821-5 [pii]10.1016/j.molcel.2006.11.026.
Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 2008;133:612–26. doi:S0092-8674(08)00441-8 [pii]10.1016/j.cell.2008.03.025.
Brooks CL, Gu W. New insights into p53 activation. Cell Res. 2010;20:614–21. doi:cr201053 [pii]10.1038/cr.2010.53.
Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203–6. doi:10.1038/378203a0.
Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378:206–8. doi:10.1038/378206a0.
Parant J, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001;29:92–5. doi:10.1038/ng714 [pii].
Johnson TM, Hammond EM, Giaccia A, Attardi LD. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet. 2005;37:145–52. doi:ng1498 [pii]10.1038/ng1498.
Li M, et al. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003;302:1972–5. doi:10.1126/science.1091362302/5652/1972 [pii].
Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 2007;26:923–34. doi:7601560 [pii]10.1038/sj.emboj.7601560.
Kruse JP, Gu W. MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem. 2009;284:3250–63. doi:M805658200 [pii]10.1074/jbc.M805658200.
Ahn BY, et al. Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer. Oncogene. 2010;29:1155–66. doi:onc2009413 [pii]10.1038/onc.2009.413.
Li M, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 2002;416:648–53. doi:10.1038/nature737 [pii].
Muscolini M, et al. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. J Biol Chem. 2011;286:39693–702. doi:M111.279539 [pii]10.1074/jbc.M111.279539.
Sykes SM, Stanek TJ, Frank A, Murphy ME, McMahon SB. Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem. 2009;284:20197–205. doi:M109.026096 [pii]10.1074/jbc.M109.026096.
Yamaguchi H, et al. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 2009;284:11171–83. doi:M809268200 [pii]10.1074/jbc.M809268200.
Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene. 2008;27:6507–21. doi:onc2008315 [pii]10.1038/onc.2008.315.
Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006;13:962–72. doi:4401914 [pii]10.1038/sj.cdd.4401914.
Pozniak CD, et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000;289:304–6.
Okada Y, et al. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. Exp Cell Res. 2002;276:194–200. doi:10.1006/excr.2002.5535S0014482702955357 [pii].
Katoh I, Aisaki KI, Kurata SI, Ikawa S, Ikawa Y. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene. 2000;19:3126–30. doi:10.1038/sj.onc.1203644.
Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004;18:3041–54. doi:18/24/3041 [pii]10.1101/gad.1221004.
Gressner O, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005;24:2458–71. doi:7600708 [pii]10.1038/sj.emboj.7600708.
Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998;58:5061–5.
Melino G, et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem. 2004;279:8076–83. doi:10.1074/jbc.M307469200 [pii].
Sayan AE, et al. P73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene. 2008;27:4363–72. doi:onc200864 [pii]10.1038/onc.2008.64.
John K, Alla V, Meier C, Putzer BM. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ. 2011;18:874–86. doi:cdd2010153 [pii]10.1038/cdd.2010.153.
Suh EK, et al. p63 protects the female germ line during meiotic arrest. Nature. 2006;444:624–8. doi:nature05337 [pii]10.1038/nature05337.
Kerr JB, et al. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol Cell. 2012;48:343–52. doi:S1097-2765(12)00735-6 [pii]10.1016/j.molcel.2012.08.017.
Flores ER, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7:363–73. doi:S1535-6108(05)00092-9 [pii]10.1016/j.ccr.2005.02.019.
Tomasini R, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008;22:2677–91. doi:gad.1695308 [pii]10.1101/gad.1695308.
Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene. 2007;26:5169–83. doi:1210337 [pii]10.1038/sj.onc.1210337.
Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221–7. doi:10.1038/ni0302-221 [pii].
Rosette C, Karin M. Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science. 1996;274:1194–7.
McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev. 2012;246:311–26. doi:10.1111/j.1600-065X.2012.01101.x.
Miyamoto S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take center stage. Cell Res. 2011;21:116–30. doi:cr2010179 [pii]10.1038/cr.2010.179.
Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344–62. doi:S0092-8674(08)00120-7 [pii]10.1016/j.cell.2008.01.020.
Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853–66. doi:10.1038/sj.onc.1203239.
Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195–224. doi:10.1101/gad.122870418/18/2195 [pii].
Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell. 2003;115:565–76. doi:S009286740300895X [pii].
Mabb AM, Wuerzberger-Davis SM, Miyamoto S. PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress. Nat Cell Biol. 2006;8:986–93. doi:ncb1458 [pii]10.1038/ncb1458.
Wu ZH, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 2006;311:1141–6. doi:311/5764/1141 [pii]10.1126/science.1121513.
Jin HS, et al. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res. 2009;69:1782–91. doi:0008-5472.CAN-08-2256 [pii]10.1158/0008-5472.CAN-08-2256.
Hinz M, et al. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol Cell. 2010;40:63–74. doi:S1097-2765(10)00710-0 [pii]10.1016/j.molcel.2010.09.008.
Wu ZH, et al. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell. 2010;40:75–86. doi:S1097-2765(10)00712-4 [pii]10.1016/j.molcel.2010.09.010.
Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. 2006;13:773–84. doi:4401843 [pii]10.1038/sj.cdd.4401843.
Kasibhatla S, et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998;1:543–51. doi:S1097-2765(00)80054-4 [pii].
Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–90. doi:S009286740300521X [pii].
Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell. 2011;145:92–103. doi:S0092-8674(11)00175-9 [pii]10.1016/j.cell.2011.02.023.
Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-kappaB activation in response to DNA damage. Cell. 2005;123:1079–92. doi:S0092-8674(05)01042-1 [pii]10.1016/j.cell.2005.09.036.
Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science. 2004;304:843–6. doi:10.1126/science.1095432 [pii].
Dorstyn L, et al. Caspase-2 deficiency promotes aberrant DNA-damage response and genetic instability. Cell Death Differ. 2012;19:1288–98. doi:cdd201236 [pii]10.1038/cdd.2012.36.
Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 2000;288:874–7. doi:8502 [pii].
Tenev T, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011;43:432–48. doi:S1097-2765(11)00420-5 [pii]10.1016/j.molcel.2011.06.006.
Ganten TM, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 2004;11 Suppl 1:S86–96. doi:10.1038/sj.cdd.4401437 [pii].
Pop C, et al. FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem J. 2011;433:447–57. doi:BJ20101738 [pii]10.1042/BJ20101738.
Oberst A, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471:363–7. doi:nature09852 [pii]10.1038/nature09852.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:S0092-8674(11)00127-9 [pii]10.1016/j.cell.2011.02.013.
Schmitt CA, et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1:289–98. doi:S1535610802000478 [pii].
Junttila MR, Evan GI. p53—a Jack of all trades but master of none. Nat Rev Cancer. 2009;9:821–9. doi:nrc2728 [pii]10.1038/nrc2728.
Bartkova J, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70. doi:nature03482 [pii]10.1038/nature03482.
Bartkova J, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633–7. doi:nature05268 [pii]10.1038/nature05268.
Gorgoulis VG, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–13. doi:nature03485 [pii]10.1038/nature03485.
Dominguez-Sola D, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007;448:445–51. doi:nature05953 [pii]10.1038/nature05953.
Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell. 2002;111:779–89. doi:S0092867402011133 [pii].
Di Micco R, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638–42. doi:nature05327 [pii]10.1038/nature05327.
d’Adda di Fagagna F, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–8. doi:10.1038/nature02118 [pii].
Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 2011;11:161–76. doi:nrc3025 [pii]10.1038/nrc3025.
Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science. 2002;297:565–9. doi:10.1126/science.297.5581.565297/5581/565 [pii].
Sfeir A, de Lange T. Removal of shelterin reveals the telomere end-protection problem. Science. 2012;336:593–7. doi:336/6081/593 [pii]10.1126/science.1218498.
O’Driscoll M, Jeggo PA. The role of double-strand break repair—insights from human genetics. Nat Rev Genet. 2006;7:45–54. doi:nrg1746 [pii]10.1038/nrg1746.
O’Driscoll M, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell. 2001;8:1175–85. doi:S1097-2765(01)00408-7 [pii].
Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8:735–48. doi:nrg2159 [pii]10.1038/nrg2159.
Savitsky K, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53.
Bell DW, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286:2528–31. doi:8128 [pii].
Stewart GS, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell. 1999;99:577–87. doi:S0092-8674(00)81547-0 [pii].
Carney JP, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell. 1998;93:477–86. doi:S0092-8674(00)81175-7 [pii].
Miki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.
Wooster R, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92. doi:10.1038/378789a0.
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747–9. doi:10.1038/348747a0.
O’Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet. 2003;33:497–501. doi:10.1038/ng1129 [pii].
Barlow C, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86:159–71. doi:S0092-8674(00)80086-0 [pii].
Bassing CH, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell. 2003;114:359–70. doi:S009286740300566X [pii].
DiTullio Jr RA, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol. 2002;4:998–1002. doi:10.1038/ncb892 [pii].
Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–98. doi:nrc3342 [pii]10.1038/nrc3342.
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204. doi:nrc2342 [pii]10.1038/nrc2342.
Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev. 2008;18:80–6. doi:S0959-437X(08)00021-X [pii]10.1016/j.gde.2008.01.016.
Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8:121–32. doi:nrc2297 [pii]10.1038/nrc2297.
Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440–2. doi:10.1038/335440a0.
Certo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–65. doi:S1535-6108(06)00113-9 [pii]10.1016/j.ccr.2006.03.027.
Del Gaizo Moore V, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117:112–21. doi:10.1172/JCI28281.
Ni Chonghaile T, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129–33. doi:science.1206727 [pii]10.1126/science.1206727.
Kastan MB, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992;71:587–97. doi:0092-8674(92)90593-2 [pii].
Armata HL, Garlick DS, Sluss HK. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res. 2007;67:11696–703. doi:67/24/11696 [pii]10.1158/0008-5472.CAN-07-1610.
Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000. doi:0092-8674(95)90214-7 [pii].
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999;1:20–6. doi:10.1038/8991.
Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91:649–59. doi:S0092-8674(00)80452-3 [pii].
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658–69.
Westphal CH, et al. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet. 1997;16:397–401. doi:10.1038/ng0897-397.
Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127:1323–34. doi:S0092-8674(06)01597-2 [pii]10.1016/j.cell.2006.12.007.
Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006;443:214–7. doi:nature05077 [pii]10.1038/nature05077.
Garcia-Cao I, et al. “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 2002;21:6225–35.
Khan SH, Moritsugu J, Wahl GM. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci U S A. 2000;97:3266–71. doi:10.1073/pnas.050560997 [pii].
Jeffers JR, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4:321–8. doi:S1535610803002447 [pii].
Villunger A, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302:1036–8. doi:10.1126/science.1090072 [pii].
Garrison SP, et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol. 2008;28:5391–402. doi:MCB.00907-07 [pii]10.1128/MCB.00907-07.
Michalak EM, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 2009;16:684–96. doi:cdd2008195 [pii]10.1038/cdd.2008.195.
Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008;15:1019–29. doi:cdd200816 [pii]10.1038/cdd.2008.16.
Finnberg N, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol. 2005;25:2000–13. doi:25/5/2000 [pii]10.1128/MCB.25.5.2000-2013.2005.
Chen L, et al. CD95 promotes tumour growth. Nature. 2010;465:492–6. doi:nature09075 [pii]10.1038/nature09075.
Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995;82:675–84. doi:0092-8674(95)90039-X [pii].
Jackson RJ, et al. p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res. 2003;63:3021–5.
Brady CA, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011;145:571–83. doi:S0092-8674(11)00312-6 [pii]10.1016/j.cell.2011.03.035.
Jiang D, et al. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc Natl Acad Sci U S A. 2011;108:17123–8. doi:1111245108 [pii]10.1073/pnas.1111245108.
Li T, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269–83. doi:S0092-8674(12)00533-8 [pii]10.1016/j.cell.2012.04.026.
Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol. 2010;2:a001040. doi:cshperspect.a001040 [pii]10.1101/cshperspect.a001040.
Ventura A, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661–5. doi:nature05541 [pii]10.1038/nature05541.
Green DR. Cell competition: pirates on the tangled bank. Cell Stem Cell. 2010;6:287–8. doi:S1934-5909(10)00103-7 [pii]10.1016/j.stem.2010.03.006.
Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell. 2010;6:309–22. doi:S1934-5909(10)00099-8 [pii]10.1016/j.stem.2010.03.002.
Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol. 2010;8:e1000324. doi:10.1371/journal.pbio.1000324.
Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol. 2012;13:579–90. doi:nrm3420 [pii]10.1038/nrm3420.
Zhao Z, et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010;24:1389–402. doi:24/13/1389 [pii]10.1101/gad.1940710.
Cicalese A, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 2009;138:1083–95. doi:S0092-8674(09)00840-X [pii]10.1016/j.cell.2009.06.048.
Maryanovich M, et al. The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells. Nat Cell Biol. 2012;14:535–41. doi:ncb2468 [pii]10.1038/ncb2468.
Zinkel SS, et al. A role for proapoptotic BID in the DNA-damage response. Cell. 2005;122:579–91. doi:S0092-8674(05)00641-0 [pii]10.1016/j.cell.2005.06.022.
Kamer I, et al. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell. 2005;122:593–603. doi:S0092-8674(05)00597-0 [pii]10.1016/j.cell.2005.06.014.
Ito K, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431:997–1002. doi:nature02989 [pii]10.1038/nature02989.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Baran, K., Rodriguez, D., Green, D. (2014). The DNA Damage Response Mediates Apoptosis and Tumor Suppression. In: Wu, H. (eds) Cell Death. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9302-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9302-0_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9301-3
Online ISBN: 978-1-4614-9302-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)